Medicine metabolic relevant loci detection method

Abstract

The invention relates to a medicine metabolic relevant loci detection method, which comprises the following steps: extracting genome DNA from human samples; respectively designing a Taqman probe pair and a primer pair according to at least two medicine metabolic relevant genes; respectively marking the 5' end and the 3'end of the Taqman probe pair with fluorescence reporting genes and fluorescence quenching genes; carrying out fluorescence quantitative PCR augmentation on the genome DNA; and judging whether the medicine metabolic relevant genes have the mutation according to the fluorescence quantitative PCR augmentation results. Preferably, the number of the medicine metabolic relevant genes is four, the Taqman probe pair and the primer pair are used for detecting a loci rs1057910 of a gene CYP2C9, a loci rs4244285 of a gene CYP2C19, a loci rs4986893of a gene CYP2C19, a loci rs1065852 of a gene CYP2D6 and a loci rs28371759 of a gene CYP3A4. The invention has the advantages of ingenious design, simple operation and accurate and reliable detection results, and provides the reference frame for determining whether professional doctors are needed to be consulted so as to make sure the medicine can be taken or not or the proper dosage and the like when a certain medicine is taken.

Description

technical field [0001] The present invention relates to the technical field of detection of function-related sites, more specifically, to the technical field of detection methods for drug metabolism-related sites, in particular to a detection method for drug metabolism-related sites. Background technique [0002] Cytochrome P450 enzymes (cytochrome P450, CYP), also known as mixed function oxidase (mixed functionoxidase) and monooxygenase (monooxygenase), mainly exist in liver microsomes, in the biological process of exogenous compounds (including drugs and poisons) It plays a very important role in the transformation. Its activity determines the metabolic rate of the drug, which is directly related to the clearance rate of the drug. It is the first phase enzyme of drug metabolism, so it is also called drug metabolizing enzyme. It metabolizes and / or activates a wide variety of drugs, as well as procarcinogens, protoxins and mutagens. The genes of P450 enzymes mainly include ...

AI Technical Summary

Problems solved by technology

Different sites of cytochrome P450 enzymes correspond to different drugs. For example, related metabolic drugs of CYP2C9 gene include anti-inflammatory and analgesic drugs (diclofenac, tiroxicam, ibuprofen, naproxen, piroxicam, mefenamic acid, fluridine Profen, indomethacin), antiepileptic drugs (phenytoin, carbamazepine), anticoagulant drugs (warfarin, dicoumarol), hypoglycemic drugs (tolbutamide, glipizide, libenclamide, glimepiride), others (losartan, torasemide, tamoxifen, dronabinol, amitriptyline), etc., while the enzyme clearance rate of CYP2C9 variant is only 15% of wild type ~20%, easy to produce side effects of substrate drugs, especially warfarin, phenytoin and some hypoglycemic drugs (such as glibenclamide, glimepiride), such as bleeding caused by S-warfarin, tolbutamide hypoglycemic shock

Images